BRIACELL THERAPEUTICS CORP. Accounts Payable, Trade, Current
BRIACELL THERAPEUTICS CORP. (BCTX) had Accounts Payable, Trade, Current of $2.17 million as of 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccountsPayableTradeCurrent · last filed 2026-06-09
- 2026-04-30: Accounts Payable, Trade, Current $2.17M.
- 2026-01-31: Accounts Payable, Trade, Current $1.88M.
- 2025-10-31: Accounts Payable, Trade, Current $2.13M.
- 2025-07-31: Accounts Payable, Trade, Current $3.28M.
| Period end | Accounts Payable, Trade, Current |
|---|---|
| 2026-04-30 | $2.17M 10-Q · filed 2026-06-09 |
| 2026-01-31 | $1.88M 10-Q · filed 2026-03-10 |
| 2025-10-31 | $2.13M 10-Q · filed 2025-12-11 |
| 2025-07-31 | $3.28M 10-Q · filed 2026-06-09 |
| 2025-04-30 | $3.28M 10-Q · filed 2025-06-16 |
| 2025-01-31 | $5.00M 10-Q · filed 2025-03-12 |
| 2024-10-31 | $4.23M 10-Q · filed 2024-12-16 |
| 2024-07-31 | $7.17M 10-K · filed 2025-10-16 |
| 2024-04-30 | $6.42M 10-Q · filed 2024-06-14 |
| 2024-01-31 | $3.71M 10-Q · filed 2024-03-18 |
| 2023-10-31 | $433.92K 10-Q · filed 2023-12-14 |
| 2023-07-31 | $1.12M 10-K · filed 2024-10-29 |
| 2023-04-30 | $995.25K 10-Q · filed 2023-06-14 |
| 2023-01-31 | $582.45K 10-Q · filed 2023-03-16 |
| 2022-10-31 | $791.75K 10-Q · filed 2022-12-14 |
| 2022-07-31 | $463.28K 10-K · filed 2023-10-25 |
| 2021-07-31 | $214.12K 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |